|
n/a
|
|
Join Date: Aug 2010
Posts: 255
|
|
|
n/a
Join Date: Aug 2010
Posts: 255
|
Reduction in mortality b/c of DMD?
That's my takeaway . Yours ?
Bolding mine
*edited in Link to article* http://www.neurology.org/content/81/2/184.short
PubMed http://www.ncbi.nlm.nih.gov/pubmed/23836941
Quote:
Mortality in patients with multiple sclerosis
Antonio Scalfari, MD,
Volker Knappertz, MD,
Gary Cutter, PhD,
Douglas S. Goodin, MD,
Raymond Ashton, PGCE and
George C. Ebers, MD
• From the Centre of Neuroscience (A.S.), Division of Experimental
Medicine, Department of Medicine, Imperial College, Hammersmith Hospital, London, UK; Department of Neurology (V.K.), Heinrich Heine University Düsseldorf, Düsseldorf, Germany; AstraZeneca–Medimmune (V.K.), Gaithersburg, MD; Section on Research Methods and Clinical Trials (G.C.), University of Alabama at Birmingham, Birmingham; Department of Neurology (D.S.G.), University of California, San Francisco; PAREXEL MMS (R.A.), West Sussex; and Nuffield Department of Clinical Neurosciences (G.E.), John Radcliffe Hospital, University of Oxford, Oxford, UK.
• Correspondence to Dr. Ebers: george.ebers@ndcn.ox.ac.uk
• doi: 10.1212/WNL.0b013e31829a3388 Neurology July 9, 2013 vol. 81 no. 2 184-192
Abstract
Mortality in patients with multiple sclerosis (MS) is significantly increased compared with the general population. Many questions concerning survival in MS are still unanswered due to the difficulty of comparing information collected at different times and in different geographic areas. The increasing incidence of MS, the improvement in care of the chronically disabled, and different methodologies may explain the lack of coherence among studies' results. Reported times to death from birth and from disease onset/diagnosis are highly variable. Patients older at onset or with primary progressive course have shorter survival; however, data on sex and mortality are contradictory. Changes in sex ratio in MS over time represent one possible explanation. MS is the main cause of death in ≥50% of patients and the incidence of deaths not due to MS varies among countries. Particularly, suicide is substantially increased in patients with MS, and, despite its varying incidence, mainly due to “cultural bias,” it should be considered an MS-related cause of death. Recent results of the long-term follow-up study of interferon-β-1b demonstrated a significant reduction of mortality among treated patients. Notwithstanding its long latency, mortality is therefore an unambiguously valid long-term outcome in randomized controlled trials. It usefully combines the net impact of treatment efficacy on longevity and adverse events, which may reduce it.
GLOSSARY
EDR=
excess death rate;
IFN=
interferon;
MHC=
major histocompatibility complex;
MS=
multiple sclerosis;
PP=
primary progressive;
RCT=
randomized clinical trial;
SMR=
standardized mortality ratio
|
Last edited by Chemar; 07-11-2013 at 06:13 PM.
Reason: adding corrected quote tags, citations and link for copyright
|